<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Difluprednate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Difluprednate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Difluprednate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9018" href="/d/html/9018.html" rel="external">see "Difluprednate: Drug information"</a> and <a class="drug drug_patient" data-topicid="12166" href="/d/html/12166.html" rel="external">see "Difluprednate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6741203"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Durezol</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868977"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Durezol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F20882302"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Corticosteroid, Ophthalmic</span></li></ul></div>
<div class="block dop drugH1Div" id="F20761378"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="beb405f3-d938-4be2-b025-e3720ea655ea">Endogenous anterior uveitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endogenous anterior uveitis:</b> Limited data available: Children ≥2 years and Adolescents: Ophthalmic: Instill 1 drop into conjunctival sac of the affected eye(s) 4 times daily for 14 days, then taper as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24677110','lexi-content-ref-22265149']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24677110','lexi-content-ref-22265149'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2a477b7a-9b72-4371-97a0-379444bbef39">Inflammation associated with ocular surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inflammation associated with ocular surgery:</b> Infants, Children, and Adolescents: Ophthalmic: Instill 1 drop in conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery, continue for 2 weeks, then decrease to 2 times daily for 1 week, then taper based on response; the initial efficacy trials were in patients 0 to 3 years of age with congenital cataracts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27367745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27367745'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109232"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51109233"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doa drugH1Div" id="F6741235"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9018" href="/d/html/9018.html" rel="external">see "Difluprednate: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="beb405f3-d938-4be2-b025-e3720ea655ea">Endogenous anterior uveitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endogenous anterior uveitis:</b>
<b>Ophthalmic:</b> Instill 1 drop into conjunctival sac of the affected eye(s) 4 times daily for 14 days, then taper as clinically indicated.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e4c896c-7ad0-4e5c-8d00-c3b8517c8488">Inflammation/pain associated with ocular surgery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inflammation/pain associated with ocular surgery:</b>
<b>Ophthalmic:</b> Instill 1 drop in conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery, continue for 2 weeks, then decrease to 2 times daily for 1 week, then taper based on response.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990551"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, systemic absorption is limited.</p></div>
<div class="block doha drugH1Div" id="F50987890"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, systemic absorption is limited.</p></div>
<div class="block adr drugH1Div" id="F6741215"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Anterior chamber inflammation (2% to 15%), blepharitis (5% to 15%), conjunctival edema (5% to 15%), corneal edema (2% to 15%), eye pain (5% to 15%), ocular hyperemia (including ciliary, conjunctival, limbal: 5% to 15%), photophobia (2% to 15%), secondary cataract (5% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (5% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (5% to 10%), decreased visual acuity (1% to 5%), dry eye syndrome (2% to 5%), eye irritation (5% to 10%), increased intraocular pressure (5% to 10%), iridocyclitis (2% to 5%), iritis (1% to 10%), ophthalmic inflammation (1% to 5%), punctate keratitis (1% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site irritation, local discomfort (application site)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal changes (pigmentation and striae), crusting of eyelid, episcleritis, eye pruritus, foreign body sensation of eye, increased lacrimation, injected sclera, macular edema</p></div>
<div class="block coi drugH1Div" id="F6741211"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Active viral (including herpes simplex keratitis, vaccinia, varicella) infections of the cornea or conjunctiva, fungal infection of ocular structures, or mycobacterial ocular infections</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to difluprednate, any component of the formulation, or to other corticosteroids; acute untreated ocular bacterial infection.</p></div>
<div class="block war drugH1Div" id="F6741212"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Use following cataract surgery may delay healing or increase the incidence of bleb formation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Corneal perforation: Perforation may occur with topical steroids in diseases which cause thinning of the cornea or sclera.</p>
<p style="text-indent:-2em;margin-left:4em;">• Exacerbation of infections: May exacerbate severity of infections. Use extreme caution in patients with history of ocular herpes simplex. Re-evaluate after 2 days if symptoms have not improved. Use is contraindicated in most viral diseases of the cornea and conjunctiva and with fungal or mycobacterial ocular infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in presence of glaucoma. Prolonged use of corticosteroids may result in elevated intraocular pressure (IOP); damage to the optic nerve; and defects in visual acuity and fields of vision. Monitor IOP in any patient receiving treatment for ≥10 days.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: May mask infection or enhance existing infection. The possibility of corneal fungal infection should be considered with persistent corneal ulceration during prolonged therapy; obtain cultures when appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Contains sorbic acid which may be absorbed by contact lenses; remove contacts prior to administration and wait 10 minutes before reinserting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For ophthalmic use only; not for intraocular administration. Initial prescription and renewal of medication for &gt;28 days should be made by health care provider only after examination with the aid of magnification such as slit lamp biomicroscopy or fluorescein staining (if appropriate). To avoid contamination, do not touch tip of container to any surface.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878722"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric patients may be at increased risk for elevations in intraocular pressure (IOP) when using difluprednate for uveitis (Birnbaum 2011; Slabaugh 2012). In one retrospective review (n=27, age range: 6 to 63 years), four of the five children (80%) treated with difluprednate had an increase in IOP of ≥5 mm Hg (two had increase ≥20 mm Hg ) compared to seven out of 22 adults (32%) (three had increase ≥20 mm Hg). Elevation of IOP responded to discontinuation of difluprednate or the addition of glaucoma medications (Birnbaum 2011). Another retrospective review of pediatric uveitis patients (n=14, age range: 7 to 18 years) described a higher incidence of cataracts in addition to increased IOP in this patient population (Slabaugh 2012).</p></div>
<div class="block foc drugH1Div" id="F6741238"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Durezol: 0.05% (5 mL) [contains edetate (edta) disodium, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (5 mL)</p></div>
<div class="block geq drugH1Div" id="F6741204"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F20958137"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Difluprednate Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $9.26 - $44.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Durezol Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per mL): $52.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868978"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Durezol: 0.05% (5 mL) [contains edetate (edta) sodium (tetrasodium), polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614282"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: For ophthalmic use only. Wash hands prior to use. Avoid contact of bottle tip with skin or eye; ocular solutions can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may occur from using contaminated solutions. Remove contact lenses prior to administration and wait at least 10 minutes before reinserting soft contact lenses. The use of the same bottle for both eyes is not recommended in surgical patients.</p></div>
<div class="block adm drugH1Div" id="F14614211"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Ophthalmic:</b> For topical ophthalmic use only; not for intraocular administration. Wash hands prior to use and avoid touching tip of dropper. Remove contact lenses prior to use. Do not reinsert contact lenses within 10 minutes of difluprednate eye drops. The use of the same bottle for both eyes is not recommended in surgical patients.</p></div>
<div class="block sts drugH1Div" id="F6741228"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Do not freeze. Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53570312"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of inflammation and pain following ocular surgery (FDA approved in pediatric patients [age not specified] and adults); treatment of endogenous anterior uveitis (FDA approved in adults) </p></div>
<div class="block mst drugH1Div" id="F9606264"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Durezol may be confused with Durasal</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Difluprednate, when used pediatric patients &lt;18 years of age, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be used with caution due to risk of increased intraocular pressure (weak recommendation, low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299195"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6741223"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13375041"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies. The amount of difluprednate absorbed systemically following ophthalmic administration is below the limit of quantification (&lt;50 ng/mL).</p></div>
<div class="block mopp drugH1Div" id="F53570313"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Intraocular pressure in any patient receiving treatment for ≥10 days; periodic examination of lens with prolonged use (&gt;28 days)</p></div>
<div class="block pha drugH1Div" id="F6741229"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Corticosteroids inhibit the inflammatory response including edema, capillary dilation, leukocyte migration, and scar formation. Difluprednate penetrates cells readily to induce the production of lipocortins. These proteins modulate the activity of prostaglandins and leukotrienes.</p></div>
<div class="block phk drugH1Div" id="F6741231"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Systemic: Exposure to active metabolite is negligible with ocular administration</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Undergoes deacetylation to an active metabolite (DFB) </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6875352"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Lupred | Neopred</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Diflupad</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Diflustero</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aropred | Baklot | Dfrot | Diflup | Diflusap | Difuvac | Duronet | Dypred | Enpred</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Enpred</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Deslotan | Dorezolol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ystan</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ystan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21555625">
<a name="21555625"></a>Birnbaum AD, Jiang Y, Tessler HH, Goldstein DA. Elevation of intraocular pressure in patients with uveitis treated with topical difluprednate. <i>Arch Ophthalmol</i>. 2011;129(5):667-668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/difluprednate-pediatric-drug-information/abstract-text/21555625/pubmed" id="21555625" target="_blank">21555625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Durezol.1">
<a name="Durezol.1"></a>Durezol (difluprednate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2020.</div>
</li>
<li>
<div class="reference">
                  Durezol (difluprednate) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19101421">
<a name="19101421"></a>Korenfeld MS, Silverstein SM, Cooke DL, et al, "Difluprednate Ophthalmic Emulsion 0.05% for Postoperative Inflammation and Pain," <i>J Cataract Refract Surg</i>, 2009, 35(1):26-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/difluprednate-pediatric-drug-information/abstract-text/19101421/pubmed" id="19101421" target="_blank">19101421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/difluprednate-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24677110">
<a name="24677110"></a>Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. <i>Invest Ophthalmol Vis Sci</i>. 2014;55(5):2993-3002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/difluprednate-pediatric-drug-information/abstract-text/24677110/pubmed" id="24677110" target="_blank">24677110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22265149">
<a name="22265149"></a>Slabaugh MA, Herlihy E, Ongchin S, van Gelder RN. Efficacy and potential complications of difluprednate use for pediatric uveitis. <i>Am J Ophthalmol</i>. 2012;153(5):932-938.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/difluprednate-pediatric-drug-information/abstract-text/22265149/pubmed" id="22265149" target="_blank">22265149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27367745">
<a name="27367745"></a>Wilson ME, O'Halloran H, VanderVeen D, et al. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. <i>Eye (Lond)</i>. 2016;30(9):1187-1194.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/difluprednate-pediatric-drug-information/abstract-text/27367745/pubmed" id="27367745" target="_blank">27367745</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 98093 Version 127.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
